Biotechnology

Seeking breakthroughs

Our goals in biotechnology are straightforward. We invest in novel science, and we seek breakthroughs – truly innovative medicines and platform technologies, and diagnostics that address critical, unmet medical needs, and that have the potential to change the practice of medicine.

We empower entrepreneurs – with capital, but also with insight based on our extensive industry experience, and with access to the executive talent and pharmaceutical companies in our professional network. Our investment team also has an extensive record of forming and growing companies. Our proprietary capabilities include in-house incubation and company creation. Our portfolio companies benefit from our venture partners – veteran entrepreneurs who work exclusively with us.

We make initial investments at levels from seed capital through early clinical development stages. And many of those investments have made a difference to patients. We have an unparalleled track record and a long history of bringing drugs from discovery, through development, and into the market. Our investment in early-stage companies has led to the identification of several new classes of drugs which have now become multibillion-dollar categories, including VGEF inhibitors (now generating over $11 billion in annual sales) and PARP inhibitors, projected to be a multibillion dollar drug category. We have supported the development of over a dozen drugs in such categories as oncology, neuroscience and infectious disease – drugs that have changed lives.

We are located where the action is. Our transatlantic biotech group is based in our offices in Boston, San Francisco and London, the top three centers of biotech innovation.

Dementia Discovery Fund

SV won the mandate to manage the Dementia Discovery Fund in August 2015 against competition from more than fifteen other specialist healthcare venture capital firms.

Dementia Discovery Fund

portfolio image

Portfolio

Current Investments

Alba Therapeutics
Alinea Pharmaceuticals
ErVaxx Limited
Juvaris BioTherapeutics
Kalvista Pharmaceuticals
Karus Therapeutics
Kesios Therapeutics Limited
NKT Therapeutics, Inc
Oxagen Limited/Atopix Therapeutics Limited
PanOptica
Pionyr Immunotherapeutics
Pulmocide
Sitryx Therapeutics Limited
Sutro Biopharma, Inc.
Thesan Pharmaceuticals
TopiVert
Vantia Pharmaceuticals
VHSquared

Previous Investments

Achillion Pharmaceuticals
Aderis Pharmaceuticals
Affibody
Affinium Pharmaceuticals
Alantos Pharmaceuticals
Allocure
Allos Therapeutics
Antiva (Vantia Spin-Out)
Archemix
Auxilium Pharmaceuticals
Avant Immunotherapeutics, Inc.
Avera Pharmaceuticals
Axys Pharmaceuticals
Celldex/Lorantis
Cellzome
Cerebrus
Cognis
Convergence Pharmaceuticals
Cyterix Pharmaceuticals
Cytomed
Delenex Therapeutics
Dynogen Pharmaceuticals
ESBATech
EUSA Pharma
Eyetech Pharmaceuticals
Geltex Pharmaceuticals
GlycoFi
Gyros AB
Ikano Therapeutics
Imagen Biotech
Incyte Pharmaceuticals
Ingenium
Itero Biopharmaceuticals
Kinetix Pharmaceuticals
KuDOS Pharmaceuticals
LeukoSite
Link Medicine
Logical Therapeutics
Lux Biosciences
Metris Therapeutics
Micromet
Mpex Pharmaceuticals
NeurogesX
Neurotech
Nigra plc
Oncoethix
Ophthotech
Orchid Chemicals
PowderMed
Quantum Dot
Rempex Pharmaceuticals
RespiVert
Rinat Neuroscience
Sapphire Therapeutics
Shire Pharmaceuticals
Solexa
Strides Arcolab
Third Wave Technologies
Triangle Pharmaceuticals
Trine Pharmaceuticals
Vanguard Medica (Vernalis)
Versicor
X2-Pharma